Fewer gastrointestinal events with vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy: analysis from the phase 3 HELIOS-B study
Abstract
Background: Patients with transthyretin amyloidosis (ATTR) with cardiomyopathy (CM) can experience extracardiac manifestations, including gastrointestinal (GI) manifestations that negatively impact their quality of life. Methods: In the double-blind HELIOS-B study, patients received vutrisiran 25 mg or placebo every 12 weeks for up to 36 months. Reported adverse events classified using preferred terms of the MedDRA GI disorders system organ class were compared between treatment arms in the overall population, the monotherapy population (not receiving tafamidis at baseline) and the baseline tafamidis subgroup. Results: Overall, 271/654 patients experienced 529 GI events, 195 in the vutrisiran arm (23.4 events per 100 patient-years) and 334 in the placebo arm (40.6 events/100 patient-years; rate ratio, 0.58; p < 0.0001). With vutrisiran, lower rates were observed for almost all GI events including constipation, diarrhea, nausea, abdominal pain and vomiting, versus placebo, with rates of overall GI events reduced by 38-49% across populations (all p < 0.0001). Reductions in mean cumulative GI events with vutrisiran versus placebo were observed from Month 3. Conclusions: Treatment with vutrisiran was associated with substantially fewer GI events versus placebo in patients with ATTR-CM, with the difference beginning early in treatment. Future trials should consider assessment of extracardiac manifestations.
Related
- Relationship between native papillary muscle T1 time and severity of functional mitral regurgitation in patients with non-ischemic dilated cardiomyopathy
- Associated factors for stress ulcers and gastrointestinal bleeding in patients with sepsis or septic shock: A systematic review
- Transthyretin Contributes to Hippocampal Blood-Brain Barrier Recovery Following Intestinal Inflammation, with Reduced Expression in Alzheimer's Disease
- Cliramitug for depletion of cardiac amyloid transthyretin: long-term follow-up of the NI006-101 trial
- Targeting Sec61 to Silence Pathogenic Light-Chain Production in AL Amyloidosis
BibTeX
@article{urey2026fewer,
title = {{Fewer gastrointestinal events with vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy: analysis from the phase 3 HELIOS-B study}},
author = {Marcus A. Urey and Quan M. Bui and Laura Obici and Jonas Wixner and Erwan Donal and Hiroaki Kitaoka and Ainara Lozano-Bahamonde and Shaun Bender and Katherine L. Boyle and Emre Aldinc and Caroline Morbach},
journal = {Amyloid: The Journal of Protein Folding Disorders},
year = {2026},
month = jul,
doi = {10.1080/13506129.2026.2695367},
url = {https://hal.science/hal-05753159v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Fewer gastrointestinal events with vutrisiran versus placebo in patients with transthyretin amyloidosis with cardiomyopathy: analysis from the phase 3 HELIOS-B study
AU - Marcus A. Urey
AU - Quan M. Bui
AU - Laura Obici
AU - Jonas Wixner
AU - Erwan Donal
AU - Hiroaki Kitaoka
AU - Ainara Lozano-Bahamonde
AU - Shaun Bender
AU - Katherine L. Boyle
AU - Emre Aldinc
AU - Caroline Morbach
PY - 2026
DA - 2026/07/17
JO - Amyloid: The Journal of Protein Folding Disorders
DO - 10.1080/13506129.2026.2695367
UR - https://hal.science/hal-05753159v1
AB - Background: Patients with transthyretin amyloidosis (ATTR) with cardiomyopathy (CM) can experience extracardiac manifestations, including gastrointestinal (GI) manifestations that negatively impact their quality of life. Methods: In the double-blind HELIOS-B study, patients received vutrisiran 25 mg or placebo every 12 weeks for up to 36 months. Reported adverse events classified using preferred terms of the MedDRA GI disorders system organ class were compared between treatment arms in the overall population, the monotherapy population (not receiving tafamidis at baseline) and the baseline tafamidis subgroup. Results: Overall, 271/654 patients experienced 529 GI events, 195 in the vutrisiran arm (23.4 events per 100 patient-years) and 334 in the placebo arm (40.6 events/100 patient-years; rate ratio, 0.58; p < 0.0001). With vutrisiran, lower rates were observed for almost all GI events including constipation, diarrhea, nausea, abdominal pain and vomiting, versus placebo, with rates of overall GI events reduced by 38-49% across populations (all p < 0.0001). Reductions in mean cumulative GI events with vutrisiran versus placebo were observed from Month 3. Conclusions: Treatment with vutrisiran was associated with substantially fewer GI events versus placebo in patients with ATTR-CM, with the difference beginning early in treatment. Future trials should consider assessment of extracardiac manifestations.
SN - 1350-6129
SN - 1744-2818
ER -